Paclitaxel News and Research

RSS

Paclitaxel is a drug used to treat breast cancer, ovarian cancer, and AIDS-related Kaposi sarcoma. It is also used together with another drug to treat non-small cell lung cancer. Paclitaxel is also being studied in the treatment of other types of cancer. It blocks cell growth by stopping cell division and may kill cancer cells. It is a type of antimitotic agent. Also called Taxol.

The Paclitaxel compound is extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). Check for active clinical trials or closed clinical trials using this agent.

Paclitaxel treatment found to directly promote HBV replication and transcription

Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy.

24 Apr 2024

Drug-coated balloon shows superiority in coronary in-stent restenosis treatment

In the largest randomized clinical trial and first of its kind to date in the United States, a team led by investigators at Beth Israel Deaconess Medical Center (BIDMC) assessed the efficacy and safety of using a drug-coated balloon in patients undergoing coronary angioplasty.

11 Mar 2024

Developing a prognostic model for bladder urothelial cancer using oxidative stress signatures

A new research paper was published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 3, entitled, "Prognostic model development and molecular subtypes identification in bladder urothelial cancer by oxidative stress signatures."

28 Feb 2024

IPIAD augments standard therapy for pancreatic ductal adenocarcinoma

A new research perspective was published in Oncoscience (Volume 11) on February 7, 2024, entitled, "IPIAD- an augmentation regimen added to standard treatment of pancreatic ductal adenocarcinoma using already-marketed repurposed drugs irbesartan, pyrimethamine, itraconazole, azithromycin, and dapsone."

9 Feb 2024

Atezolizumab plus carboplatin: A winning combination for metastatic triple-negative breast cancer

Immunotherapy in combination with chemotherapy has become an important therapeutic treatment option in some patients with metastatic breast cancer.

14 Dec 2023

Crown Bioscience launches large-scale organoid panel screening platform for accelerated preclinical oncology drug discovery

Crown Bioscience, a global contract research organization (CRO) and JSR Life Sciences company, today announced the launch of its ground-breaking service offering, OrganoidXploreTM.

13 Nov 2023

Trastuzumab deruxtecan offers added benefit for patients with HER2-low breast cancer

The antibody-drug conjugate trastuzumab deruxtecan is approved for various therapeutic indications. Since March 2023, it can also be used as monotherapy for the treatment of adults with unresectable or metastatic HER2-low breast cancer who have received prior chemotherapy at this disease stage or developed disease recurrence early after adjuvant chemotherapy.

31 Oct 2023

New study challenges long-held belief about how chemotherapy works

A new study from the University of Wisconsin–Madison suggests that chemotherapy may not be reaching its full potential, in part because researchers and doctors have long misunderstood how some of the most common cancer drugs actually ward off tumors.

26 Oct 2023

Study finds link between industry payments to oncologists and non-recommended cancer treatments

Patients with cancer whose oncologist receives payments from industry appear more likely to receive some non-recommended and low value treatments, finds a US study published by The BMJ today.

25 Oct 2023

New course of treatment with existing drugs for cervical cancer reduces risk of death by 35%

A course of treatment with existing drugs prior to chemoradiation led to a 35% reduction in the risk of death or return of cancer, in trial results presented by researchers from UCL and UCLH.

25 Oct 2023

Short course of induction chemotherapy can reduce cervical cancer relapse and death by 35%

The INTERLACE phase III trial, funded by Cancer Research UK and UCL Cancer Trials Centre, assessed whether a short course of induction chemotherapy (IC) prior to chemoradiation (CRT) could reduce the rate of relapse and death among patients with locally advanced cervical cancer.

22 Oct 2023

Nano-based cancer therapies may be less effective in younger patients, finds study

Researchers at The University of Texas MD Anderson Cancer Center have discovered that certain nano-based cancer therapies may be less effective in younger patients, highlighting the need for further investigation into the impact of aging on the body's ability to respond to treatment.

19 Sep 2023

Intensity-modulated radiation therapy reduces radiation exposure to heart and lungs in NSCLC patients

Intensity-modulated radiation therapy (IMRT) should be the preferred choice when treating patients with locally advanced non-small cell lung cancer (NSCLC), as it reduces radiation exposure to the heart and lungs, according to researchers at The University of Texas MD Anderson Cancer Center.

12 Sep 2023

Optilume BPH Catheter System offers a safe and effective treatment for benign prostatic hyperplasia

Treatment with the recently approved, minimally invasive Optilume BPH device improves urinary symptoms while preserving sexual function in men with benign prostatic hyperplasia (BPH), concludes a randomized trial in the September issue of The Journal of Urology®, an Official Journal of the American Urological Association (AUA).

10 Aug 2023

ECOG-ACRIN launches new trial to evaluate nilotinib and paclitaxel for advanced cancers

The ECOG-ACRIN Cancer Research Group has enrolled the first patient in a new treatment trial to evaluate the effectiveness of adding nilotinib to standard paclitaxel chemotherapy.

20 Jul 2023

The potential prognostic role of AhRR and PPP1R3C expression in serous ovarian cancer

Study evaluated genes with copy number alterations to identify biomarkers for ovarian cancer prognosis.

18 Jul 2023

AMP releases consensus recommendations for CYP3A4 and CYP3A5 genotyping assays

The Association for Molecular Pathology (AMP), the premier global molecular diagnostic professional society, today published consensus recommendations to aid in the design and validation of clinical CYP3A4 and CYP3A5 genotyping assays, promote standardization of testing across different laboratories, and improve patient care.

10 Jul 2023

Breast cancer patients experience more severe CIPN symptoms with paclitaxel

Chemotherapy-induced peripheral neuropathy (CIPN) – nerve pain, tingling, or numbness in the hands or feet – is a common side effect of certain cancer treatments, including two drugs frequently used to treat cancer – the taxanes paclitaxel and docetaxel.

31 May 2023

New understanding of chemotherapeutic resistance in recurring ovarian cancer

A new editorial paper was published in Oncoscience (Volume 10) on May 11, 2023, entitled, "UPR-induced ovarian cancer cell fusion: a mechanism favoring drug resistance?"

26 May 2023

Spinal cord stimulation may help reduce chronic pain in people undergoing active cancer treatment

Researchers at Johns Hopkins University School of Medicine say they have evidence from a new study in rats that spinal cord stimulation (SCS) may be useful in reducing chronic pain in people undergoing active treatment with a common anti-cancer drug.

From Elekta 27 Apr 2023